表紙
市場調查報告書

內分泌療法藥的全球市場:2020年∼2024年

Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 356778
出版日期 內容資訊 英文 120 Pages
訂單完成後即時交付
價格
Back to Top
內分泌療法藥的全球市場:2020年∼2024年 Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024
出版日期: 2020年02月05日內容資訊: 英文 120 Pages
簡介

全球內分泌療法藥市場在2020年∼2024年的預測期間內,預計將以7%的年複合成長率增長,達到247億8,000萬美元的規模。內分泌障礙的發生率增加是市場成長主要因素之一。此外,肥胖與內分泌失調之間的聯繫有望推動市場增長。

本報告提供全球內分泌療法藥市場相關調查分析,提供市場規模及成長率,市場趨勢,推動市場要素,課題,市場機會驗證,再加上主要供應商等相關的系統性資訊。

目錄

第1章 摘要整理

第2章 市場的狀況

  • 市場生態系統

第3章 市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模(2019年)
  • 市場預測:2019-2024年的預測

第4章 波特的五力分析

  • 買主談判力
  • 供應商談判力
  • 新加入廠商的威脅
  • 替代品的威脅
  • 對手的威脅
  • 市場情況

第5章 市場區隔:各治療領域

  • 糖尿病治療藥-市場規模與預測2019-2024
  • hGH-市場規模與預測2019-2024
  • 甲狀腺荷爾蒙障礙-市場規模與預測2019-2024
  • 睪酮(睪丸激素)替代療法-市場規模與預測2019-2024
  • 其他-市場規模與預測2019-2024

第6章 客戶狀況

第7章 各地區形勢

  • 各地區市場區隔
  • 北美-市場規模與預測2019-2024
  • 歐洲-市場規模與預測2019-2024
  • 亞洲-市場規模與預測2019-2024
  • 其他地區-市場規模與預測2019-2024
  • 主要國家
  • 市場機會:各地區

第8章 成長要素,課題,及趨勢

  • 市場成長要素
  • 市場課題
  • 市場趨勢

第9章 供應商的展望

  • 概要
  • 業者情勢
  • 形勢的創新

第10章 供應商分析

  • 交易廠商
  • 供應商的市場定位
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc

第11章 附錄

  • 調查範圍
  • 美金的貨幣換算比率
  • 調查方法
  • 簡稱的清單

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR40785

Technavio has been monitoring the global endocrinology drugs market and it is poised to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders . In addition, association between obesity and endocrine disorders is anticipated to boost the growth of the global endocrinology drugs market as well.

Market Segmentation

Technavio's global endocrinology drugs market is segmented as below:

Therapy area

  • Diabetes Drugs
  • Thyroid Hormone Disorder Drugs
  • HGH
  • Testosterone Replacement Therapy
  • Others

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global endocrinology drugs market growth

This study identifies association between obesity and endocrine disorders as the prime reasons driving the global endocrinology drugs market growth during the next few years.

Prominent vendors in global endocrinology drugs market

We provide a detailed analysis of around 25 vendors operating in the global endocrinology drugs market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Eli Lilly and Co., GlaxoSmithKline Plc, Groupe Sanofi, Merck & Co. Inc., Novartis International AG, Novo Nordisk AS and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Diabetes drugs - Market size and forecast 2019-2024
  • hGH - Market size and forecast 2019-2024
  • Thyroid hormone disorders - Market size and forecast 2019-2024
  • Testosterone replacement therapy - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Other1 placement - Market share 2019-2024 (%)
  • 23.Comparison by Other1 placement
  • 24.Diabetes drugs - Market size and forecast 2019-2024 ($ billion)
  • 25.Diabetes drugs - Year-over-year growth 2019-2024 (%)
  • 26.hGH - Market size and forecast 2019-2024 ($ billion)
  • 27.hGH - Year-over-year growth 2019-2024 (%)
  • 28.Thyroid hormone disorders - Market size and forecast 2019-2024 ($ billion)
  • 29.Thyroid hormone disorders - Year-over-year growth 2019-2024 (%)
  • 30.Testosterone replacement therapy - Market size and forecast 2019-2024 ($ billion)
  • 31.Testosterone replacement therapy - Year-over-year growth 2019-2024 (%)
  • 32.Others - Market size and forecast 2019-2024 ($ billion)
  • 33.Others - Year-over-year growth 2019-2024 (%)
  • 34. Market opportunity by Other1
  • 35.Customer landscape
  • 36.Market share by geography 2019-2024 (%)
  • 37.Geographic comparison
  • 38.North America - Market size and forecast 2019-2024 ($ billion)
  • 39.North America - Year-over-year growth 2019-2024 (%)
  • 40.Europe - Market size and forecast 2019-2024 ($ billion)
  • 41.Europe - Year-over-year growth 2019-2024 (%)
  • 42.Asia - Market size and forecast 2019-2024 ($ billion)
  • 43.Asia - Year-over-year growth 2019-2024 (%)
  • 44.ROW - Market size and forecast 2019-2024 ($ billion)
  • 45.ROW - Year-over-year growth 2019-2024 (%)
  • 46.Key leading countries
  • 47.Market opportunity by geography ($ billion)
  • 48.Impact of drivers
  • 49.Impact of challenges
  • 50.Landscape disruption
  • 51.Industry risks
  • 52.Vendors covered
  • 53.Market positioning of vendors
  • 54.Abbott Laboratories - Overview (1/3)
  • 55.Abbott Laboratories - Overview (2/3)
  • 56.Abbott Laboratories - Overview (3/3)
  • 57.Abbott Laboratories - Business segments
  • 58.Abbott Laboratories - Key offerings
  • 59.Abbott Laboratories - Key customers
  • 60.Abbott Laboratories - Segment focus
  • 61.AbbVie Inc. - Overview (1/3)
  • 62.AbbVie Inc. - Overview (2/3)
  • 63.AbbVie Inc. - Overview (3/3)
  • 64.AbbVie Inc. - Business segments
  • 65.AbbVie Inc. - Key offerings
  • 66.AbbVie Inc. - Key customers
  • 67.AbbVie Inc. - Segment focus
  • 68.AstraZeneca Plc - Overview (1/3)
  • 69.AstraZeneca Plc - Overview (2/3)
  • 70.AstraZeneca Plc - Overview (3/3)
  • 71.AstraZeneca Plc - Product and service
  • 72.AstraZeneca Plc - Key offerings
  • 73.AstraZeneca Plc - Key customers
  • 74.AstraZeneca Plc - Segment focus
  • 75.Eli Lilly and Co. - Overview (1/3)
  • 76.Eli Lilly and Co. - Overview (2/3)
  • 77.Eli Lilly and Co. - Overview (3/3)
  • 78.Eli Lilly and Co. - Business segments
  • 79.Eli Lilly and Co. - Key offerings
  • 80.Eli Lilly and Co. - Key customers
  • 81.Eli Lilly and Co. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview (1/3)
  • 83.GlaxoSmithKline Plc - Overview (2/3)
  • 84.GlaxoSmithKline Plc - Overview (3/3)
  • 85.GlaxoSmithKline Plc - Business segments
  • 86.GlaxoSmithKline Plc - Key offerings
  • 87.GlaxoSmithKline Plc - Key customers
  • 88.GlaxoSmithKline Plc - Segment focus
  • 89.Groupe Sanofi - Overview (1/3)
  • 90.Groupe Sanofi - Overview (2/3)
  • 91.Groupe Sanofi - Overview (3/3)
  • 92.Groupe Sanofi - Business segments
  • 93.Groupe Sanofi - Key offerings
  • 94.Groupe Sanofi - Key customers
  • 95.Groupe Sanofi - Segment focus
  • 96.Merck & Co. Inc. - Overview (1/3)
  • 97.Merck & Co. Inc. - Overview (2/3)
  • 98.Merck & Co. Inc. - Overview (3/3)
  • 99.Merck & Co. Inc. - Business segments
  • 100.Merck & Co. Inc. - Key offerings
  • 101.Merck & Co. Inc. - Key customers
  • 102.Merck & Co. Inc. - Segment focus
  • 103.Novartis International AG - Overview (1/3)
  • 104.Novartis International AG - Overview (2/3)
  • 105.Novartis International AG - Overview (3/3)
  • 106.Novartis International AG - Business segments
  • 107.Novartis International AG - Key offerings
  • 108.Novartis International AG - Key customers
  • 109.Novartis International AG - Segment focus
  • 110.Novo Nordisk AS - Overview (1/3)
  • 111.Novo Nordisk AS - Overview (2/3)
  • 112.Novo Nordisk AS - Overview (3/3)
  • 113.Novo Nordisk AS - Business segments
  • 114.Novo Nordisk AS - Key offerings
  • 115.Novo Nordisk AS - Key customers
  • 116.Novo Nordisk AS - Segment focus
  • 117.Pfizer Inc. - Overview (1/3)
  • 118.Pfizer Inc. - Overview (2/3)
  • 119.Pfizer Inc. - Overview (3/3)
  • 120.Pfizer Inc. - Business segments
  • 121.Pfizer Inc. - Key offerings
  • 122.Pfizer Inc. - Key customers
  • 123.Pfizer Inc. - Segment focus
  • 124.Currency conversion rates for US$
  • 125.Research Methodology
  • 126.Validation techniques employed for market sizing
  • 127.Information sources
  • 128.List of abbreviations
Back to Top